Company Overview and News

 
Nitta Gelatin seeks protection for Thrissur plant, properties

2017-11-09 thehindubusinessline
Nitta Gelatin India Ltd, a joint venture of KSIDC and Nitta Gelatin Group of Japan, has sought protection for its plant and properties at Kathikudam in Thrissur district and urged the government to take stern action against the miscreants.

 
After being cut to the bone, gelatin industry sees better times ahead

2017-10-12 thehindubusinessline
After apex court reins in cow vigilantism, non-availability of cattle bones is a thing of the past, says industry

 
Nitta Gelatin India reports standalone net loss of Rs 1.29 crore in the June 2017 quarter

2017-07-29 indiainfoline
Nitta Gelatin India reports standalone net loss of Rs 1.29 crore in the June 2017 quarter

 
AstraZeneca Pharma, Nitta Gelatin down 4-9% on poor Q4 numbers

2017-05-10 moneycontrol
Share price of AstraZeneca Pharma and Nitta Gelatin India declined 4 percent and 9 percent respectively intraday Wednesday on poor March quarter (Q4) numbers.

 
Nitta Gelatin confident of a turnaround

2017-03-03 thehindubusinessline
Nitta Gelatin India Ltd is hopeful of garnering more business, thanks to raw-material availability at more reasonable costs and also the Centre’s recent revision of the regulations relating to crushed bone imports.

 
Top buzzing midcap stocks to trade on November 7

2016-11-07 moneycontrol
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Godrej Consumer Products, Lupin, PNB Housing Finance, Punjab National Bank, Cyeint, Federal-Mogul Goetze, Nitta Gelatin India, Vakrangee, Umang Dairies, Tera Sofwtare, Titan, Dalmia Bharat, Seshasayee Paper and Boards, Future Retail and Heritage Foods

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...